This dual nature is particularly evident in chronic kidney disease patients, where elevated sclerostin levels correlate with increased cardiovascular events, yet simultaneously show potential cardioprotective properties through the regulation of vascular calcification. The gene discussed is SOST; the disease is chronic kidney disease.